Related Experiment Videos
Population pharmacokinetics of the novel anticancer agent KRN7000
Mirjam Crul1, Ron A Mathôt, Giuseppe Giaccone
1The Netherlands Cancer Institute, Department of Medical Oncology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. apmcr@slz.nl
Purpose:
KRN7000 is a novel anticancer agent, acting through stimulation of the immune system. The first clinical trial with this agent, which included pharmacokinetic studies, has recently been completed. The aim of the study presented here was to develop a population pharmacokinetic model for KRN7000.
Methods:
Plasma concentration-time data were gathered from 24 patients enrolled in a phase I trial in which KRN7000 was administered as a weekly slow injection at doses ranging from 50 to 4800 microg/m(2). These data were used to build a pharmacokinetic model using the nonlinear mixed-effect modeling (NONMEM) program. The model was validated by performance of 200 bootstraps.
Results:
A three-compartment model with interindividual variability on the central and two peripheral volumes of distribution (V1, V2 and V3) and on clearance (CL) adequately described the data. The final estimates were: V1 2.34 l, V2 2.61 l, V3 2.13 l, and CL 0.130 l/h. Of 24 covariates tested, including both demographic and pathophysiological factors, none showed a significant relationship with the pharmacokinetic parameters obtained. The bootstrap analysis provided parameter estimates within approximately 15% of the original estimates, indicating stability of the model.
Conclusion:
The pharmacokinetic behavior of KRN7000 in the clinical trial could be described by a three-compartment model. Hence, KRN7000 demonstrates linear pharmacokinetics over the investigated dose range. The pharmacokinetics of KRN7000 are not influenced by patient demographic or pathophysiological characteristics.
Insights
This study developed a population pharmacokinetic model for KRN7000, a novel anticancer agent. Results show KRN7000 exhibits linear pharmacokinetics and is unaffected by patient characteristics.
Area of Science:
- Pharmacology
- Immunology
- Oncology
Background:
- KRN7000 is a novel immunomodulatory anticancer agent.
- Early clinical trials have included pharmacokinetic assessments.
- Understanding KRN7000 pharmacokinetics is crucial for optimizing its therapeutic use.
Purpose of the Study:
- To develop a population pharmacokinetic model for KRN7000.
- To characterize the pharmacokinetic behavior of KRN7000 in cancer patients.
- To establish a basis for future KRN7000 dosing strategies.
Main Methods:
- Plasma concentration-time data from 24 patients in a Phase I trial were analyzed.
- Nonlinear mixed-effects modeling (NONMEM) was employed to build the pharmacokinetic model.
- Model validation was performed using 200 bootstrap replicates.
Main Results:
- A three-compartment model adequately described KRN7000 pharmacokinetics.
- Key pharmacokinetic parameters included central and peripheral volumes of distribution and clearance.
- No significant influence of demographic or pathophysiological covariates on pharmacokinetic parameters was observed.
Conclusions:
- KRN7000 exhibits linear pharmacokinetics across the studied dose range.
- The established pharmacokinetic model accurately describes KRN7000 behavior in patients.
- Patient-specific factors do not appear to significantly alter KRN7000 pharmacokinetics.